Want to see CTXR full AI Analyst Report?
CTXR Stock Chart & Stats
$0.60
-$0.01(-2.07%)
At close: 4:00 PM EDT
$0.60
-$0.01(-2.07%)
Day’s Range― - ―
52-Week Range$0.47 - $2.19
Previous CloseN/A
Volume176.71K
Average Volume (3M)835.38K
Market Cap
$16.13M
Enterprise Value$15.28
Total Cash (Recent Filing)$17.01M
Total Debt (Recent Filing)$7.18M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Dec 17, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding27,452,570
10 Day Avg. Volume546,573
30 Day Avg. Volume835,378
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.87
Revenue Forecast (FY)$20.84M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company reported positive top-line data from the P3 study, achieving its primary endpoint of increase in time to catheter failure.
Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory GuidanceThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Bears Say
Capital RequirementsCitius Pharma needs to secure additional capital prior to a launch of Lymphir.
Financial ConstraintsThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.
Regulatory Approval TimelineCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.
Citius Pharmaceuticals News
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.47 and its highest was $2.19 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Citius Pharmaceuticals’s market cap is $16.13M.
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Dec 17, 2026 which is in 101 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.02.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 27,452,570 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -25.563%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Currently, no hedge funds are holding shares in CTXR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Stock 12 Month Forecast
Average Price Target
$4.00
▲(566.67% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Palatin Technologies
―
Daré Bioscience
―
Lipocine
―
KALA BIO
―
Ownership Overview
1.49%
Insiders
3.15% Mutual Funds
0.85% Other Institutional Investors
93.78% Public Companies and
Individual Investors